25 . 07 .2024
Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance
19 . 06 .2024
Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence
23 . 05 .2024
Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets
07 . 05 .2024
Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries
21 . 03 .2024
Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow
19 . 03 .2024
Press release
AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio
13 . 03 .2024
Press release
Galderma launches IPO on the SIX Swiss Exchange and sets price range
10 . 03 .2024
Press release
Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis
29 . 02 .2024
Press release
Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion